Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC-004
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SC-004 is an antibody-drug conjugate (ADC) developed for the treatment of metastatic solid tumors, including ovarian cancer and related gynecological malignancies. It consists of a proprietary monoclonal antibody targeting tumor-associated antigens Claudin 6 (CLDN6) and Claudin 9 (CLDN9), linked to an undisclosed cytotoxic agent. The mechanism involves inhibition of CLDN6 and CLDN9, which are overexpressed in certain cancers, leading to targeted delivery of the cytotoxic payload to tumor cells. The drug was originally developed by Stemcentrx and later by AbbVie following acquisition. Clinical development reached phase 1 but has since been discontinued for indications such as endometrial carcinoma, fallopian tube carcinoma, ovarian epithelial carcinoma, and peritoneal cancer[1][4][5].
- Other names
- ADC SC-004Antibody-drug conjugate SC-004
02
Targets
CLDN9 (Claudin 9)CLDN6 (Claudin-6)
Beyond the preview
Go deeper on SC-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SC-004.